Transplant and Stem Cell Immunobiology (TSI) Lab »  People »  Principal Investigators »  Sonja Schrepfer, M.D., Ph.D.
Sonja Schrepfer, M.D., Ph.D.

Sonja Schrepfer, M.D., Ph.D.

Associate Professor of Surgery
Division of Adult Cardiothoracic Surgery
Director, TSI Lab

Contact Information

Open Popup
  • University of Wuerzburg and Munich, Germany MD 10/2001 Medicine, Immunology
  • University of Wuerzburg, Germany Doctoral Thesis 05/2002 Medicine, Immunology
  • University of Hamburg, Germany and Stanford University, Stanford, CA PhD 01/2007 Experimental Cardiac Surgery, Transplant Immunobiology
  • Stanford University, Stanford, CA Postdoctoral Training and Instructor 02/2009 Cardiothoracic Surgery, Transplant Immunobiology
  • 2005 - 2007 Postdoctoral Fellow, Transplant Immunology Laboratory, Stanford University, School of Medicine, CT Surgery. Advisor: Dr. Robert C. Robbins
  • 2007 - 2009 Instructor, Transplant Immunology Laboratory, Stanford University, School of Medicine, CT Surgery
  • 2009-2015 Professor and Founder, Transplant and Stem Cell Immunobiology (TSI) Laboratory, University Heart Center Hamburg, Germany
  • Cardiovascular MechanismsiInvolved in Vessel Stenosis
  • Pluripotent Stem Cell Immunobiology
  • Transplant Immunology
  • Vascular Biology of Mice During Space Travel
  • German, French

Sonja Schrepfer, M.D., Ph.D. founded the Transplant and Stem Cell Immunobiology (TSI) Lab in 2009. In 2016, she joined the faculty of the Department of Surgery at the University of California San Francisco (UCSF) as Associate Professor. She is also Director of the TSI Lab at UCSF.

Dr. Schrepfer's research career has been dedicated to making fundamental discovers in stem cell immunology, transplant and cardiovascular immunobiology. Her lab currently works on immunobiological mechanisms of pluripotent stem cells (mouse and human). One project uses e.g. a combination of molecular/cellular biology, genomic/epigenomic profiling, tissue engineering, and molecular imaging technologies to better understand stem cell biology in vitro and in vivo. She has made significant contributions in the field of immunological barriers in regenerative medicine and in identifying novel immunobiological targets involved in cardiovascular diseases.

The TSI Lab is also investigating the vascular biology of "mice from space"; that is mice that have spent time at the international space station (ISS). This research will provide insight into what physiological effects time in outer space might have on astronauts, with potentially important implications for future longer-term missions, and has the possibility to open the door to fascinating new discoveries that could be used in earth-bound cardiovascular research.

Dr. Schrepfer's research aims to understand the critical immunological barrier that presently precludes the successful application of cell-based regenerative therapy Her TSI Lab has made seminal contributions to the field, including the first description of the antigenicity of mitochondria in embryonic stem cells derived by somatic cell nucleus transfer (SCNT). Currently, her group is interested in understanding the molecular, cellular, and epigenetic landscape changes after transplantation of stem cells and their derivates and we are aiming to decrease the immunogenic potential of PSCs.

The lab has also discovered novel pathways involved in the development of vascular intimal hyperplasia. Myointimal hyperplasia is a pathological process of the vascular system characterized by abnormal proliferation of smooth muscle cells of the vascular wall that leads to luminal obliteration and subsequent ischemia. Myointimal hyperplasia may occur in patients after vessel injury during medical procedures (e.g. after balloon dilation or stent placement) or after pathological injury of the blood vessel (e.g. due to inflammation or toxic exposure). It can cause graft failure and in-stent restenosis. To help prevent this and increase the success of treatments for coronary heart disease, Dr. Schrepfer's   lab has also developed novel humanized models to study the development of intimal hyperplasia.

Transplant immunology after heart and lung transplantation is another area the lab is exploring with particular focus on translational research and investigation of underlying mechanisms of acute and chronic graft rejection. Novel drug discoveries will benefit our patients tremendously.

Most recent publications from a total of 77
  1. Mitsutake Y, Reifart J, Pyun WB, Lyons JK, Deuse T, Schrepfer S, Ikeno F. Differences in Vascular Response between Balloon Overstretch and Stent Overexpansion in Nonatherosclerotic Porcine Coronary Arteries. Comp Med. 2017 Aug 01; 67(4):350-355. View in PubMed
  2. Miller KK, Wang D, Hu X, Hua X, Deuse T, Neofytou E, Renne T, Velden J, Reichenspurner H, Schrepfer S, Bernstein D. Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study. Transpl Int. 2017 Jul 03. View in PubMed
  3. Barac YD, Emrich F, Krutzwakd-Josefson E, Schrepfer S, Sampaio LC, Willerson JT, Robbins RC, Ciechanover A, Mohr FW, Aravot D, Taylor DA. The ubiquitin-proteasome system: A potential therapeutic target for heart failure. J Heart Lung Transplant. 2017 Jul; 36(7):708-714. View in PubMed
  4. Wang D, Tediashvili G, Pecha S, Reichenspurner H, Deuse T, Schrepfer S. Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency. J Vis Exp. 2017 Jan 15; (119). View in PubMed
  5. Guihaire J, Itagaki R, Stubbendorff M, Hua X, Deuse T, Ullrich S, Fadel E, Dorfmüller P, Robbins RC, Reichenspurner H, Schumacher U, Schrepfer S. Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder. Transpl Int. 2016 Dec; 29(12):1337-1348. View in PubMed
  6. Guenther SP, Schrepfer S. miR-126: a potential new key player in hypoxia and reperfusion? Ann Transl Med. 2016 Oct; 4(19):377. View in PubMed
  7. Deuse T, Hua X, Stubbendorff M, Spin JM, Neofytou E, Taylor V, Chen Y, Park G, Fink JB, Renne T, Kiefmann M, Kiefmann R, Reichenspurner H, Robbins RC, Schrepfer S. The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation. Transplantation. 2016 May; 100(5):1022-31. View in PubMed
  8. Schrepfer S, Cantu E, Gandy K, Baan CC, West LJ. "Bioengineered lungs" Best science paper in JHLT 2014-2015. J Heart Lung Transplant. 2016 Apr; 35(4):544-6. View in PubMed
  9. Gupta SK, Itagaki R, Zheng X, Batkai S, Thum S, Ahmad F, Van Aelst LN, Sharma A, Piccoli MT, Weinberger F, Fiedler J, Heuser M, Heymans S, Falk CS, Förster R, Schrepfer S, Thum T. miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovasc Res. 2016 May 15; 110(2):215-26. View in PubMed
  10. Guihaire J, Deuse T, Wang D, Fadel E, Reichenspurner H, Schrepfer S. Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade. Biomed Res Int. 2015; 2015:765292. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Sonja Schrepfer, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.